Moxonidine

Spécifications

75438-57-2Numéro CAS

629-833-3Numéro CE

4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amineNom IUPAC

C9H12ClN5OFormule chimique

241.68 g/molMasse molaire

MOXONIDINE; 75438-57-2; Norcynt; Nucynt; Cynt; Moxonidina; Moxonidinum; 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine; DTXSID5045170; BDF5896; LY326869; CC6X0L40GW; BE5895; BE-5895; 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-; BDF-5896; LY-326869; DTXCID3025170; 4-Chloro-5-(2-imidazolidinyldeneamino)-6-methoxy-2-methylpyrimidine; moxonidin; Fisiotens; Normatens; RefChem:819554; C02AC05; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine; BDF5895; LY 326869; BDF 5895; 4-chloro-N-imidazolidin-2-ylidene-6-methoxy-2-methylpyrimidin-5-amine; Lomox; BE 5895; MFCD00865794; CHEMBL19236; 4-Chloro-5-(2-imidazolin-2-ylamino)-6-methoxy-2-methylpyrimidine; NCGC00015649-02; Normoxocin; BDF-5895; CAS-75438-57-2; 4-chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine; Moxonidinum [Latin]; Moxonidina [Spanish]; Moxonidine hydrochloride hydrate; Moxonidine [INN]; UNII-CC6X0L40GW; Moxonidine [USAN:INN:BAN]; SR-01000075981; Moxonidine CRS; Moxonidine; 4-Chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine; 75438-57-2 (free base); 2-(6-Chloro-4-methoxy-2-methylpyrimidin-5-ylamino)-2-i midazoline; Moxonidine (Standard); Cynt (TN); MOXONIDINE [MI]; Moxonidine (USAN/INN); Prestwick0_001016; Prestwick1_001016; Prestwick2_001016; Prestwick3_001016; Lopac-M-1559; MOXONIDINE [USAN]; Monoxidine [common misspelling of Moxonidine]; MOXONIDINE [MART.]; MOXONIDINE [WHO-DD]; Lopac0_000753; SCHEMBL49143; BSPBio_001171; MLS002222183; SPBio_003042; BPBio1_001289; CHEBI:7009; orb1224068; orb1310011; SCHEMBL7476864; SCHEMBL29363838; GTPL12574; HY-B0374R; MOXONIDINE [EP MONOGRAPH]; GLXC-10505; HMS1571K13; HMS2098K13; HMS2230B15; HMS3373O04; HMS3655B17; HMS3715K13; HMS3747A03; HMS5080K04; Moxonidine 1.0 mg/ml in Methanol; ALBB-022451; EX-A3409; HY-B0374; MSK10672; Tox21_110190; 2-(6-Chloro-4-methoxy-2-methylpyrimidin-5-ylamino)-2-imidazoline; 4-chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine; AC-637; BDBM50050093; EBC-26285; MFCD22689455; PDSP1_000177; PDSP2_000176; s2066; STL419983; AKOS015895873; AKOS015997932; Tox21_110190_1; AF-0062; CCG-204838; DB09242; SDCCGSBI-0050731.P002; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-pyrimidin-5-amine; NCGC00015649-01; NCGC00015649-04; NCGC00015649-05; NCGC00015649-08; NCGC00015649-11; NCGC00015649-15; NCGC00015649-17; NCGC00092355-02; FM165499; SMR000857402; AB00514003; M2660; NS00007154; SW196502-4; C07451; D05087; AB00514003-08; AB00514003_10; EN300-7360649; F372972; Q419944; SR-01000075981-7; BRD-K77771411-001-04-4; BRD-K77771411-001-12-7; BRD-K77771411-003-10-7; (4-Chloro-6-methoxy-2-methyl-pyrimidin-5-yl)-imidazolidin-2-ylidene-amine; 4-chloro-N-(imidazolin-2-ylidene)-6-methoxy-2-methyl-5-pyrimidinamine; 5-pyrimidinamine, 4-chloro-N-2-imidazolidinylidene-6-methoxy-2-methyl-; 2-(4-Chloro-6-methoxy-2-methyl-pyrimidin-5-ylamino)-4,5-dihydro-3H-imidazol-1-ium; 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- (9CI); (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid; 1008754-16-2Synonymes